David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, outlines potential mechanisms underlying menstrual-related migraine.
A drop in estrogen or magnesium can trigger a drop in oxytocin, which plays a role in the likelihood of a migraine, said David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine.
Transcript:
What are some of the unique characteristics of menstrual-related migraine that make the condition so difficult to treat and understand?
The mechanisms underlying regular migraine headache, that is nonmenstrual related, are relatively well-understood. And some of the same mechanisms seem to be involved with menstrual migraine. But there's another layer on top having to do with fluctuations over the menstrual cycle and hormones, but other things too. Those other things may also—for example, magnesium, I'll just mention that. Those things may also play a role in regular migraine, but you don't have these monthly fluctuations that you do with menstrual migraine.
Can you expand on some of the theories regarding the pathogenic relationship between menstruation and migraine?
So kind of the most well-known thing that happens with menstrual migraine is changes in estrogen levels over the month. There's a big drop in estrogen levels just prior to menses. The theory of the mechanism underlying menstrual migraine had to do, forever, with this drop in estrogen. But it was never really clear why a drop in estrogen would cause a migraine. It turns out, though, that estrogen is not the only thing that's changing over the menstrual cycle.
One more step back, which is why oxytocin is important. What we've shown in the past is that the trigeminal nerve provides all the pain information from the head and the face. It's a great big 3-branch nerve. You have to have activity in that nerve in order to have a migraine, because, like I said, it carries all the pain information into the central nervous system. It turns out that oxytocin can inhibit the excitability of those neurons. In other words, it can act sort of as a thermostat, to turn up or turn down the sensitivity of those trigeminal neurons to input. For example, a lot of people with migraine are very sensitive to light, to a glare, or to red wine, or stress. But in order to trigger a migraine, those things don't always produce a migraine, right? The idea is that the sensitivity of these trigeminal nerves allow a trigger that might not otherwise produce a migraine to trigger the migraine.
The oxytocin, acting through oxytocin receptors, can change how sensitive or excitable those trigeminal neurons are. Well, there are things that can modulate how effective that oxytocin is. It turns out that one of the things that can change that is estrogen. How effective that oxytocin is can be modulated by basically 3 different things. One is how much oxytocin there is around. If you don't have much oxytocin, you're not going to have much activity at the receptor and the trigeminal nerve. Two, how many of those receptors there are. Because, if you only have 2 receptors and you have a bunch of oxytocin, it's still not going to do much, because it's activity at those receptors that change how excitable those neurons are. Three is what we call the affinity of the receptor, that is how tightly bound oxytocin is to that receptor. That can actually be changed too. So all those things are changeable.
It turns out that some of the things that change over the menstrual cycle can impact those things. So estrogen is an example. Estrogen can actually increase the amount of oxytocin there is available by activating the cells that make oxytocin. Estrogen could also increase the number of those oxytocin receptors on the trigeminal nerve. What happens if you drop your estrogen, you also drop your oxytocin because estrogen drives oxytocin. If you have a drop in estrogen, you have a drop in the amount of oxytocin, you also have a drop in how many oxytocin receptors there are. You have a lot less oxytocin receptor activity happening. When that happens, oxytocin, which normally decreases how excitable those nerves are, there isn't enough activity and so the excitability goes up. Triggers that may not always trigger migraine can now trigger a migraine.
There are other factors too, like magnesium. How much magnesium is in your blood changes over the menstrual cycle. Magnesium affects how tightly bound oxytocin is to its receptor, or the affinity. What that means is that when you have a drop in magnesium, you have a decrease in oxytocin receptor activity. It's no longer inhibiting how excitable those nerves are, and your excitability goes up. And once again, you're more sensitive to triggers. That's what happens. So, over the menstrual cycle, you have a big increase during ovulation of estrogen, you also have an increase in oxytocin. Then during premenstrual, then menses, you have a big drop in estrogen and you have a big drop in oxytocin and you have a drop in magnesium. Some women, if they take a magnesium supplement, [it] actually decreases their likelihood of having one of these migraines.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
2 Commerce Drive
Cranbury, NJ 08512